Ignite Creation Date:
2025-12-25 @ 4:05 AM
Ignite Modification Date:
2026-06-19 @ 6:56 PM
Study NCT ID:
NCT01035502
Status:
COMPLETED
Last Update Posted:
2013-09-27
First Post:
2009-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Sponsor:
Clavis Pharma
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CP4055-205
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None